Travoprost (CAS: 157283-68-6) is a high-performance synthetic prostaglandin F2α analogue and FP prostanoid receptor agonist, specifically developed for ophthalmic use. As a leading treatment for open-angle glaucoma and ocular hypertension, this API effectively reduces intraocular pressure through its unique mechanism of action. Travoprost distinguishes itself from other prostaglandin analogues through superior receptor selectivity and full agonist activity, delivering enhanced therapeutic efficacy with minimal side effects.
As an innovative prodrug formulation, Travoprost exhibits excellent corneal penetration properties. Following topical administration, it undergoes biotransformation to travoprost free acid, its pharmacologically active form. The API's carefully engineered structure features an isopropyl ester that optimizes ocular bioavailability. The active metabolite works by enhancing aqueous humor outflow through both trabecular meshwork and uveoscleral pathways, resulting in consistent and reliable intraocular pressure reduction. These characteristics make Travoprost a premium choice for pharmaceutical manufacturers seeking a well-documented, highly effective API for ophthalmic formulations.
